Hiring Trend Watchpoints
High-performing operators in Precision Oncology & Tumor Profiling are exhibiting aggressive expansion in commercial and sales teams, particularly to drive adoption of new, high-value diagnostic tests like MRD and early cancer detection. This is evidenced by Natera's significant investment in its commercial team, Guardant Health's expansion of its 400+ professional field organization and accelerated investments in lab capacity, Castle Biosciences' increased personnel costs for sales force and administrative functions, and Personalis's investment in commercial resources and internal salesforce build-out. Concurrently, there's a strong emphasis on R&D hiring for next-generation sequencing, AI/ML development, and advanced assay development, as seen with NeoGenomics' targeted R&D investments and Tempus AI's continuous investment in GPU capacity for AI models. Automation is also being deployed across operations to enhance efficiency and allow existing talent to focus on higher-value tasks. Watchpoints for investors: Confirming theme execution (bullish): Continued growth in job postings for sales, medical affairs, and market access roles, especially those focused on new product launches (e.g., MRD, multi-cancer early detection). Increased hiring for AI/ML engineers, bioinformatics specialists, and genomics researchers. Announcements of new lab facilities or capacity expansions. Mentions of automation leading to significant cost efficiencies or faster turnaround times without compromising quality. Warning of deterioration (bearish): Hiring freezes or significant reductions in commercial or R&D headcount. A shift in job postings away from growth-oriented roles towards administrative or cost-cutting positions. Delays in new product launches attributed to staffing shortages or lack of specialized talent. Increased reliance on external consultants for core R&D or commercialization tasks.
Forum Watchlist
subreddit — r/oncologyhigh
Physician and researcher discussions on new diagnostic tests, clinical utility, treatment pathways, and real-world evidence.
subreddit — r/cancermedium
Patient experiences, advocacy for early detection/personalized treatment, and discussions around test accessibility and reimbursement challenges.
forum — ASCO Connection Forumshigh
Oncologist perspectives on guideline changes, adoption of precision oncology tests, and clinical trial results impacting diagnostic use.
subreddit — r/genomicsmedium
Technical discussions on sequencing technologies, bioinformatics, AI in diagnostics, and emerging research relevant to tumor profiling.
forum — Liquid Biopsy Association Forumhigh
Industry and clinical discussions specific to liquid biopsy advancements, competitive landscape, and regulatory pathways.
Industry Publications
- GenomeWeb (genomeweb.com) — Comprehensive coverage of genomics, molecular diagnostics, liquid biopsy, and precision medicine, including business, research, and regulatory news, highly relevant for all theme constituents.
- Fierce Biotech (fiercebiotech.com) — Covers biotech industry news, clinical trials, FDA approvals, and company strategies, crucial for tracking diagnostic companies and their biopharma partnerships.
- MedTech Dive (medtechdive.com) — Focuses on the medical device and diagnostics industry, including market trends, regulatory changes, reimbursement, and business developments affecting precision oncology.
- STAT News (statnews.com) — Provides in-depth journalism on biotech, pharma, health policy, and scientific research, offering broader context and investigative pieces on the diagnostics landscape.
- Endpoints News (endpts.com) — Covers biopharma news, clinical trials, and M&A, which is relevant for tracking partnerships between diagnostic companies and drug developers, as well as industry consolidation.
Second Order Trends
Several second-order trends are shaping the Precision Oncology & Tumor Profiling theme: 1. AI/ML as a Core Diagnostic and Data Monetization Engine: Beyond simply processing data, AI and machine learning are becoming integral to diagnostic platforms (e.g., Guardant's InfinityAI, Tempus's foundation models) for biomarker discovery, treatment selection, and even predicting disease progression. Tempus AI's "Data Owner" model, leveraging its multimodal data library for high-margin pharmaceutical partnerships, exemplifies a new business model emerging from this trend. 2. Accelerated Push into Multi-Cancer Early Detection (MCED): The significant investment by Natera in its FIND study and Guardant Health's Shield test for early colorectal and multi-cancer detection highlights a major strategic pivot towards proactive cancer screening in asymptomatic populations. This represents a massive, largely untapped market opportunity that could fundamentally shift cancer care. 3. Differentiation in MRD: Tumor-Informed vs. Tumor-Naïve: The competitive landscape in Molecular Residual Disease (MRD) testing is intensifying, with companies like Personalis (NeXT Personal) emphasizing the ultrasensitivity and clinical necessity of tumor-informed approaches, while others like Guardant (Reveal) also push for highly sensitive, tissue-free solutions. The market is increasingly scrutinizing the clinical utility and performance differences between these methodologies. 4. Strategic M&A and Consolidation for Technology Stacks: The planned acquisition of Personalis by Tempus AI signals a trend towards consolidation, where larger players are integrating specialized, high-sensitivity technologies to strengthen their comprehensive precision oncology platforms. This suggests that smaller, highly focused innovators may become attractive targets for companies seeking to expand their capabilities and market share. 5. Focus on Community Oncology Market Penetration: Companies like NeoGenomics are strategically targeting the community oncology setting, where the majority of cancer patients receive treatment. This involves tailoring commercial strategies, developing user-friendly platforms (e.g., Epic Aura integration), and building strong relationships with community oncologists, recognizing their unique needs and resource constraints.
Search Keywords Brand Product
- Signatera MRD
- Guardant360 Liquid
- Guardant Reveal
- Shield blood test
- NeXT Personal
- PanTracer Liquid
- RaDaR ST
- OncoExTra
- Oncotype DX
- Decipher Prostate
- clonoSEQ
- DecisionDx-Melanoma
- OncoCompass
- CanCatch MRD
- Genomic Prostate Score
- TissueCypher
- AdvanceAD-Tx
Search Keywords Policy Regulatory
- FDA approval diagnostics
- MolDx coverage
- NCCN guidelines cancer
- Medicare reimbursement diagnostics
- ADLT designation
- CLFS rate schedules
- PMDA approval Japan
- IVDR certification EU
- ACS guidelines
Search Keywords Event Phrases
- Tempus AI acquisition
- ASCO conference
- AACR conference
- FIND study enrollment
- SIGNAL program launch
- Japan Signatera launch
- Shield UnitedHealth coverage
- AdvanceAD-Tx crosswalk vote
- Tempus AI IPO
Google Trend Product Category Intent
• Signatera test
• Guardant360 test
• Guardant Reveal test
• Shield cancer screening
• NeXT Personal test
• PanTracer test
• RaDaR ST test
• OncoExTra test
• Oncotype DX test
• Decipher Prostate test
• clonoSEQ test
• DecisionDx-Melanoma test
• TissueCypher test
• AdvanceAD-Tx test
Google Trend Consumer Intent
• liquid biopsy cancer
• precision oncology
• tumor profiling
• cancer genetic testing
• MRD test
• early cancer detection
• personalized cancer treatment
• cancer recurrence monitoring
• cancer biomarker testing
Google Trend Macro Policy Terms
• cancer screening guidelines
• FDA diagnostic approval
• Medicare cancer test coverage
• NCCN cancer guidelines
Economic Data Watch
1. FRED (Federal Reserve Economic Data) — National Health Expenditure Accounts
Not in registryaccess=api
Metric/field Total Health Expenditures (TEXPAM)
Cadence quarterly
Why it matters Overall healthcare spending indicates the market size and health for diagnostic services, directly impacting the addressable market for precision oncology.
Signal to watch Sustained growth or acceleration in total health expenditures is bullish, indicating a supportive macro environment for diagnostic companies.
Confidence: high
2. PhRMA (Pharmaceutical Research and Manufacturers of America) — Annual Report on Pharmaceutical R&D Spending
Not in registry
Metric/field Total R&D Spending by Biopharmaceutical Companies (USD billions)
Cadence annually
Why it matters Biopharma companies are key partners and customers for precision oncology firms, especially for drug development, biomarker discovery, and companion diagnostics. Increased R&D spending signals more opportunities.
Signal to watch Increasing or stable R&D spending is bullish, suggesting continued investment in areas that leverage precision oncology diagnostics.
Confidence: high
3. Bureau of Economic Analysis (BEA) — Personal Consumption Expenditures
Not in registryaccess=api
Metric/field Personal Consumption Expenditures: Health Care (PCEHC)
Cadence monthly
Why it matters While many precision oncology tests are reimbursed, general consumer willingness and ability to spend on healthcare services can reflect overall economic health and indirectly influence early screening or elective diagnostic uptake.
Signal to watch Consistent growth in PCE for healthcare is bullish, indicating a healthy consumer environment that supports healthcare utilization.
Confidence: medium
4. Bureau of Labor Statistics (BLS) — Producer Price Index by Industry
Not in registryaccess=api
Metric/field PPI for Medical and Diagnostic Laboratories (PCU621511621511)
Cadence monthly
Why it matters This index tracks the average change over time in the selling prices received by domestic producers for their output. For diagnostic companies, it reflects input costs (e.g., reagents, labor) and potential pricing power, impacting gross margins.
Signal to watch Stable or declining PPI is bullish, indicating manageable input costs; significant increases could signal margin pressure.
Confidence: high
5. Federal Reserve — Federal Funds Rate
Not in registry
Metric/field Effective Federal Funds Rate (FEDFUNDS)
Cadence daily
Why it matters Interest rates directly impact the cost of capital for diagnostic companies, especially those with high R&D investments, cash burn, or convertible debt, influencing their ability to fund growth and acquisitions.
Signal to watch Stable or declining rates are bullish, reducing financing costs and supporting investment in growth initiatives.
Confidence: high
Free Alt Data Watch
1. Google Trends — Search Interest
Not in registry
Metric/field Search interest for 'liquid biopsy' (relative search volume)
Cadence weekly
Why it matters Indicates public and professional interest and awareness in a core technology of the theme, signaling potential for broader adoption and market growth.
Signal to watch Increasing or stable search volume is bullish, suggesting growing interest and potential demand.
Confidence: medium
2. ClinicalTrials.gov — Study Database
Not in registry
Metric/field Number of new interventional studies for 'oncology diagnostics' (by study start date)
Cadence monthly
Why it matters Tracks the pipeline of new diagnostic tests and clinical evidence generation, which is crucial for regulatory approvals and market adoption in precision oncology.
Signal to watch An increasing number of new studies is bullish, indicating robust innovation and future product development.
Confidence: medium
3. FDA.gov — Medical Devices Approvals and Clearances
Not in registry
Metric/field Number of new 510(k) clearances or PMA approvals for 'oncology diagnostic devices' (monthly/quarterly)
Cadence monthly
Why it matters Regulatory approvals are critical milestones for commercialization and market access for precision oncology tests, directly impacting revenue potential.
Signal to watch A consistent or increasing pace of approvals is bullish, indicating a favorable regulatory environment and expanding market opportunities.
Confidence: high
4. NCCN.org (National Comprehensive Cancer Network) — Clinical Practice Guidelines in Oncology
Not in registry
Metric/field Updates to NCCN Clinical Practice Guidelines in Oncology (version changes for relevant cancer types, e.g., bladder, colorectal, breast)
Cadence event_driven
Why it matters Inclusion of specific precision oncology tests or technologies in NCCN guidelines is a significant driver of physician adoption and reimbursement coverage.
Signal to watch Positive updates or new inclusions of theme-relevant diagnostics are bullish, accelerating market penetration.
Confidence: high
5. PubMed.gov (National Library of Medicine) — Biomedical Literature Database
Not in registry
Metric/field Number of research articles published with keywords 'precision oncology' AND 'liquid biopsy' (monthly/quarterly)
Cadence monthly
Why it matters Reflects the academic and research community's focus on the theme, indicating scientific validation and potential for future clinical applications and innovation.
Signal to watch A growing number of publications is bullish, suggesting increasing scientific interest and evidence supporting the field.
Confidence: medium
Paid Alt Data Watch
1. IQVIA / Symphony Health — Medical Claims Data
Matchediqvia_medical_claims · access=file · map_only
Metric/field Test volume for CPT codes 81479, 0016M, 0020M, 0005M (molecular oncology diagnostics)
Cadence irregular
Why it matters Provides granular, independent data on actual test utilization and market share for key precision oncology products, complementing company-reported figures and indicating real-world adoption.
Signal to watch Consistent month-over-month growth in test volumes for relevant CPT codes is bullish, indicating strong market adoption.
Confidence: high
2. Revelio Labs / Thinknum — Job Postings Data
Not in registryaccess=file
Metric/field Total job postings for 'oncology sales specialist' AND 'diagnostics' by theme companies (trend)
Cadence monthly
Why it matters Indicates theme companies' hiring trends and investment in commercial expansion, signaling confidence in market growth and ability to drive sales of precision oncology tests.
Signal to watch Increasing job postings in sales and commercial roles are bullish, suggesting aggressive market penetration strategies.
Confidence: high
3. Sermo / InCrowd (Physician Survey Data) — Physician Sentiment & Adoption Surveys
Not in registry
Metric/field Physician adoption rate and perception of 'tumor-informed MRD tests' (percentage of oncologists using/recommending)
Cadence quarterly
Why it matters Direct insight into physician acceptance and integration of advanced MRD testing into clinical practice, which is crucial for sustained volume growth and reimbursement.
Signal to watch Increasing adoption rates and positive perception are bullish, indicating growing clinical utility and market acceptance.
Confidence: high
4. Komodo Health / Trilliant Health — Prescription/Diagnostic Order Data
Not in registry
Metric/field Number of unique ordering physicians for 'precision oncology tests' (monthly/quarterly trend)
Cadence monthly
Why it matters Tracks the breadth of physician engagement and adoption of precision oncology diagnostics, indicating market penetration beyond early adopters.
Signal to watch A growing number of unique ordering physicians is bullish, signaling expanding market reach and physician confidence.
Confidence: high
5. Illumina / Thermo Fisher Scientific (Sales Data) — Genomic Sequencing Instrument Sales
Not in registry
Metric/field Quarterly sales volume of 'next-generation sequencing (NGS) platforms' to clinical laboratories
Cadence quarterly
Why it matters NGS platforms are foundational technology for many precision oncology tests. Increased sales to clinical labs indicate underlying investment and expansion in genomic testing capabilities across the industry.
Signal to watch Increasing sales volume of NGS platforms to clinical labs is bullish, suggesting a growing infrastructure for precision oncology.
Confidence: medium
